封面
市場調查報告書
商品編碼
1668001

寵物疫苗市場 - 全球產業規模、佔有率、趨勢、機會和預測,按動物類型、按疫苗接種、按給藥方式、按地區和競爭進行細分,2020-2030 年預測

Pet Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Animal Type, By Vaccination, By Mode Of Administration, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 184 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球寵物疫苗市場價值為 113.1 億美元,預計到 2030 年將達到 161 億美元,複合年成長率為 6.04%。隨著寵物擁有量的不斷增加,人們越來越重視預防性醫療保健,包括接種疫苗,以保護動物免受傳染病的侵害。獸醫保健技術的進步促進了更有效疫苗的開發,確保更好地預防狂犬病、犬瘟熱和細小病毒等疾病。隨著獸醫服務的普及以及透過診所、醫院和線上平台獲得寵物疫苗的機會的增加,進一步促進了市場的擴張。製造商正在投入研發,以推出療效更強、保護時間更長的下一代疫苗。

市場概況
預測期 2026-2030
2024 年市場規模 113.1 億美元
2030 年市場規模 161億美元
2025-2030 年複合年成長率 6.04%
成長最快的領域 鼻內疫苗
最大的市場 北美洲

生物技術的創新以及 DNA 和重組疫苗的興起正在改變市場格局。公司正專注於開發聯合疫苗,只需注射一次即可提供針對多種疾病的免疫力,減少寵物看獸醫的頻率並提高寵物的依從性。伴侶動物疫苗(尤其是狗和貓疫苗)的需求不斷成長,推動了市場成長。政府推動動物疫苗接種計劃的舉措和強制免疫的嚴格規定正在增強市場活力。寵物保險覆蓋範圍的擴大(擴大包括疫苗接種費用)正在鼓勵寵物主人投資預防性醫療保健。可支配收入的增加和寵物的人性化(主人將動物視為家庭成員)也助長了寵物疫苗需求的不斷成長。

主要市場促進因素

伴侶動物疾病盛行率不斷上升

主要市場挑戰

疫苗接種成本高昂

主要市場趨勢

個人化寵物疫苗需求不斷成長

目錄

第 1 章:產品概述

第 2 章:研究方法

第 3 章:執行摘要

第 4 章:顧客之聲

第5章:全球寵物疫苗市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依動物類型(犬科動物、貓科動物、馬科動物)
    • 依疫苗接種(犬科動物、貓科動物、其他)
    • 依接種方式分類(注射疫苗、鼻腔疫苗)
    • 按公司分類(2024)
    • 按地區
  • 市場地圖

第 6 章:北美寵物疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美:國家分析
    • 墨西哥
    • 加拿大

第 7 章:歐洲寵物疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲:國家分析
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章:亞太寵物疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區:國家分析
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章:南美洲寵物疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲:國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章:中東和非洲寵物疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA:國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章:市場動態

  • 驅動程式
  • 挑戰

第 12 章:市場趨勢與發展

  • 合併與收購(如有)
  • 產品發布(如果有)
  • 最新動態

第 13 章:波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章:競爭格局

  • Bayer AG
  • Elanco US Inc.
  • Merck KGaA
  • Merial Inc.
  • Virbac SA
  • Zoetis Inc
  • Phibro Animal Health Corporation
  • Boehringer Ingelheim GmbH
  • Tianjin Ringpu Bio-Technology Co., Ltd
  • Vetoquinol SA

第 15 章:策略建議

第16章 關於出版商,免責事項

簡介目錄
Product Code: 19025

Global Pet Vaccine Market was valued at USD 11.31 Billion in 2024 and is expected to reach USD 16.10 Billion in the forecast period with a CAGR of 6.04% through 2030. The global pet vaccine market is experiencing significant growth, driven by increasing pet adoption and rising awareness about animal health. As pet ownership continues to rise, there is a growing emphasis on preventive healthcare, including vaccination, to protect animals from infectious diseases. Veterinary healthcare advancements have led to the development of more effective vaccines, ensuring better protection against diseases such as rabies, distemper, and parvovirus. The expanding availability of veterinary services and improved access to pet vaccines through clinics, hospitals, and online platforms are further contributing to market expansion. Manufacturers are investing in research and development to introduce next-generation vaccines with enhanced efficacy and longer protection duration.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 11.31 Billion
Market Size 2030USD 16.10 Billion
CAGR 2025-20306.04%
Fastest Growing SegmentIntranasal Vaccines
Largest MarketNorth America

Innovations in biotechnology and the rise of DNA and recombinant vaccines are transforming the market landscape. Companies are focusing on developing combination vaccines that provide immunity against multiple diseases with a single shot, reducing the frequency of veterinary visits and improving pet compliance. The rising demand for companion animal vaccines, particularly for dogs and cats, is fueling market growth. Government initiatives promoting animal vaccination programs and stringent regulations mandating immunization are strengthening market dynamics. The expansion of pet insurance coverage, which increasingly includes vaccination costs, is encouraging pet owners to invest in preventive healthcare. Increasing disposable income and the humanization of pets, where owners treat animals as family members, are also contributing to the growing demand for pet vaccines.

Key Market Drivers

Increasing Prevalence of Diseases in Companion Animals

The increasing prevalence of diseases in companion animals is a significant driver of the global pet vaccine market. In 2023, the World Health Organization (WHO) reported that rabies causes an estimated 59,000 human deaths annually, with dogs responsible for 99% of these transmissions. This alarming statistic underscores the critical need for effective vaccination programs to control rabies in canine populations, thereby protecting both animal and human health. Similarly, the WHO has highlighted concerns about psittacosis, a zoonotic disease transmitted from birds to humans. In February 2024, several European countries, including Austria, Denmark, Germany, Sweden, and the Netherlands, reported an increase in psittacosis cases observed in 2023 and early 2024, particularly since November-December 2023. These instances exemplify the rising incidence of zoonotic diseases, emphasizing the necessity for comprehensive vaccination strategies in companion animals.

Veterinary professionals and regulatory bodies are actively promoting routine vaccination schedules to curb the spread of these highly contagious diseases among pets. Government-led initiatives and vaccination mandates in several countries are reinforcing immunization practices, ensuring broader coverage among companion animals. For instance, the WHO recommends that vaccinating at least 70% of dogs in areas at risk is the most effective way of preventing human rabies deaths. This strategy not only safeguards animal health but also significantly reduces the risk of zoonotic disease transmission to humans. The increasing urbanization and closer human-animal interactions have raised concerns about zoonotic disease transmission, prompting pet owners to prioritize vaccinations as a preventive measure. In densely populated areas, the risk of disease outbreaks among pets is higher, making immunization an essential part of pet healthcare.

The increasing number of pet owners worldwide has been a driving force behind the expansion of veterinary healthcare facilities. For example, in countries such as the United States, over 90 million households now own pets, which has created a larger market for pet healthcare services. This surge in pet ownership has prompted veterinary clinics to expand their operations and offer more comprehensive healthcare solutions. At the same time, advancements in veterinary care, such as improved diagnostic tools and treatment options, have made it easier for clinics to provide effective care, including timely vaccinations for pets.

Government initiatives also play a crucial role in supporting the growth of veterinary healthcare infrastructure. Several countries have implemented programs to promote animal health and strengthen the veterinary workforce, including funding for veterinary clinics and training for veterinary professionals. This, in turn, ensures greater access to vaccines for pets and contributes to higher vaccination rates. As more pet owners seek professional care for their animals, the demand for dog vaccines continues to rise, further fueling the market's growth. Improved infrastructure and government support are creating a favorable environment for increased pet vaccination, thereby driving the expansion of the pet vaccine market.

Key Market Challenges

High Cost of Vaccination

One of the major challenges facing the global pet vaccine market is the high cost of vaccination, which can limit access to essential preventive healthcare for pets, particularly in lower-income regions. The price of vaccines varies depending on the type of vaccine, the brand, and the country in which they are administered. Vaccination costs are influenced by several factors, including the research and development expenses involved in creating new vaccines, regulatory fees, and distribution costs. For example, combination vaccines, which provide protection against multiple diseases in one dose, can be more expensive than single vaccines, further escalating the overall cost for pet owners.

In addition to the direct costs of vaccines, pet owners may incur additional charges for veterinary consultations and health assessments to determine which vaccines are needed for their dogs. This makes the vaccination process financially challenging for individuals, especially in regions where veterinary care is not subsidized or where pet healthcare is not covered by insurance. According to a report from the American Kennel Club, a basic vaccination package for a dog in the U.S. can cost anywhere from USD 75 to USD 150, depending on the vaccines included. More advanced vaccines or those for rare diseases may cost even more. These costs can be a significant burden for pet owners in developing countries or low-income households, potentially resulting in lower vaccination rates.

Key Market Trends

Increasing Demand for Personalized Pet Vaccines

The increasing demand for personalized pet vaccines represents a notable trend in the Pet Vaccine Market. This trend reflects a growing recognition that not all pets are alike, and tailoring vaccines to an individual animal's specific needs can yield significant benefits. Personalized pet vaccines involve customizing vaccination schedules and formulations based on factors such as a pet's age, breed, lifestyle, and geographic location. This approach ensures that each pet receives the most appropriate and effective protection against diseases, optimizing their overall health and minimizing unnecessary vaccinations. Advances in veterinary diagnostics, including genetic testing and serological assays, allow for a more precise understanding of a pet's immune status and susceptibility to specific diseases. This information can inform personalized vaccine recommendations. Pet owners increasingly view their pets as members of the family and are willing to invest in their well-being. They seek out veterinary practices that offer tailored healthcare plans, including personalized vaccines, to ensure the best outcomes for their pets.

Concerns about over-vaccination have led to a more selective approach to vaccinations. Personalization allows veterinarians to minimize unnecessary vaccinations, reducing the potential for adverse reactions and vaccine-related health issues. Regional disease prevalence varies, and some areas may have specific disease risks. Personalized vaccines can address these geographical variations, providing pets with targeted protection. In summary, the demand for personalized pet vaccines is driven by a shift toward individualized pet care and a desire to optimize vaccine effectiveness while minimizing risks. This trend aligns with the broader movement toward personalized medicine and is likely to continue shaping the Pet Vaccine Market in the coming years.

Key Market Players

  • Bayer AG
  • Elanco US Inc.
  • Merck KGaA
  • Merial Inc.
  • Virbac SA
  • Zoetis Inc
  • Phibro Animal Health Corporation
  • Boehringer Ingelheim GmbH
  • Tianjin Ringpu Bio-Technology Co., Ltd
  • Vetoquinol SA

Report Scope:

In this report, the Global Pet Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pet Vaccine Market, By Animal Type:

  • Canine
  • Feline
  • Equine

Pet Vaccine Market, By Vaccination:

  • Canine Family
  • Feline Family
  • Others

Pet Vaccine Market, By Mode Of Administration:

  • Injectable Vaccines
  • Intranasal Vaccines

Pet Vaccine Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Pet Vaccine Market.

Available Customizations:

Global Pet Vaccine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Pet Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Animal Type (Canine, Feline, Equine)
    • 5.2.2. By Vaccination (Canine Family, Feline Family, Others)
    • 5.2.3. By Mode Of Administration (Injectable Vaccines, Intranasal Vaccines)
    • 5.2.4. By Company (2024)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Pet Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Animal Type
    • 6.2.2. By Vaccination
    • 6.2.3. By Mode Of Administration
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pet Vaccine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Animal Type
        • 6.3.1.2.2. By Vaccination
        • 6.3.1.2.3. By Mode Of Administration
    • 6.3.2. Mexico Pet Vaccine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Animal Type
        • 6.3.2.2.2. By Vaccination
        • 6.3.2.2.3. By Mode Of Administration
    • 6.3.3. Canada Pet Vaccine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Animal Type
        • 6.3.3.2.2. By Vaccination
        • 6.3.3.2.3. By Mode Of Administration

7. Europe Pet Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Animal Type
    • 7.2.2. By Vaccination
    • 7.2.3. By Mode Of Administration
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Pet Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Animal Type
        • 7.3.1.2.2. By Vaccination
        • 7.3.1.2.3. By Mode Of Administration
    • 7.3.2. Germany Pet Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Animal Type
        • 7.3.2.2.2. By Vaccination
        • 7.3.2.2.3. By Mode Of Administration
    • 7.3.3. United Kingdom Pet Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Animal Type
        • 7.3.3.2.2. By Vaccination
        • 7.3.3.2.3. By Mode Of Administration
    • 7.3.4. Italy Pet Vaccine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Animal Type
        • 7.3.4.2.2. By Vaccination
        • 7.3.4.2.3. By Mode Of Administration
    • 7.3.5. Spain Pet Vaccine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Animal Type
        • 7.3.5.2.2. By Vaccination
        • 7.3.5.2.3. By Mode Of Administration

8. Asia-Pacific Pet Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Animal Type
    • 8.2.2. By Vaccination
    • 8.2.3. By Mode Of Administration
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Pet Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Animal Type
        • 8.3.1.2.2. By Vaccination
        • 8.3.1.2.3. By Mode Of Administration
    • 8.3.2. India Pet Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Animal Type
        • 8.3.2.2.2. By Vaccination
        • 8.3.2.2.3. By Mode Of Administration
    • 8.3.3. South Korea Pet Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Animal Type
        • 8.3.3.2.2. By Vaccination
        • 8.3.3.2.3. By Mode Of Administration
    • 8.3.4. Japan Pet Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Animal Type
        • 8.3.4.2.2. By Vaccination
        • 8.3.4.2.3. By Mode Of Administration
    • 8.3.5. Australia Pet Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Animal Type
        • 8.3.5.2.2. By Vaccination
        • 8.3.5.2.3. By Mode Of Administration

9. South America Pet Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Animal Type
    • 9.2.2. By Vaccination
    • 9.2.3. By Mode Of Administration
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Pet Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Animal Type
        • 9.3.1.2.2. By Vaccination
        • 9.3.1.2.3. By Mode Of Administration
    • 9.3.2. Argentina Pet Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Animal Type
        • 9.3.2.2.2. By Vaccination
        • 9.3.2.2.3. By Mode Of Administration
    • 9.3.3. Colombia Pet Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Animal Type
        • 9.3.3.2.2. By Vaccination
        • 9.3.3.2.3. By Mode Of Administration

10. Middle East and Africa Pet Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Animal Type
    • 10.2.2. By Vaccination
    • 10.2.3. By Mode Of Administration
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Pet Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Animal Type
        • 10.3.1.2.2. By Vaccination
        • 10.3.1.2.3. By Mode Of Administration
    • 10.3.2. Saudi Arabia Pet Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Animal Type
        • 10.3.2.2.2. By Vaccination
        • 10.3.2.2.3. By Mode Of Administration
    • 10.3.3. UAE Pet Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Animal Type
        • 10.3.3.2.2. By Vaccination
        • 10.3.3.2.3. By Mode Of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Bayer AG
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Elanco US Inc.
  • 14.3. Merck KGaA
  • 14.4. Merial Inc.
  • 14.5. Virbac SA
  • 14.6. Zoetis Inc
  • 14.7. Phibro Animal Health Corporation
  • 14.8. Boehringer Ingelheim GmbH
  • 14.9. Tianjin Ringpu Bio-Technology Co., Ltd
  • 14.10. Vetoquinol SA

15. Strategic Recommendations

16. About Us & Disclaimer